

Freedom of Information Request: Our Reference CTMUHB_515_23

You asked:

I am conducting analysis on drugs used to treat inflammatory diseases and kindly request your help.

I would be grateful if you could tell me how many patients were treated by individual drugs from the dermatology, gastroenterology, and rheumatology departments (for any disease) in three months from the start of August 2023 to the end of October 2023 (or the latest available 3 months).

I have provided a grid of drug names and department names requested in appendix A (below). Please fill in the grid with the numbers of patients (or forward in a format that best suits you) and include data for all hospitals in the organisation (question 1).

Appendix A

Q1 – How many patients were treated with the following drugs from the following departments (for any disease) in the 3 months between the start of Aug 2023 and the end of Oct 2023?

Please use the latest available 3 months if August to October is not available and specify which 3 months has been used.

Drug Name	Dermatology	Gastroenterology	Rheumatology
Adalimumab (Humira)	5	7	82
Adalimumab (Biosimilars)	51	160	369
Apremilast	59		16
Bimekizumab	17		
Brodalumab	5		
Certolizumab Pegol	7		57
Deucravacitinib	0	0	0
Etanercept (Enbrel)			28
Etanercept (Biosimilars)			298
Guselkumab	30		**
Infliximab (Remicade)		**	**
Infliximab (Biosimilars)	0	226	19
Ixekizumab	18		19
Risankizumab	48		
Secukinumab	5		89
Tildrakizumab	14		

Ustekinumab	39	148	16
Upadacitinib	11	14	13
Vedolizumab			186
Filgotinib		**	5
Golimumab		**	60
Mirikizumab		0	
Ozanimod		0	
Tofacitinib		**	11
Abatacept			52
Baricitinib	7		33
Rituximab			28
Sarilumab			5
Tocilizumab			89

Our response:

Please see provided in the table above data for the period 1st August 2023 to 31st October 2023 as requested.

Where the figures are less than 5, this has been denoted by **. The exact figures have been withheld due to the low numbers involved.

Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test.